

# Yi Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2328013/publications.pdf>

Version: 2024-02-01

190  
papers

34,466  
citations

41627

51  
h-index

4983

173  
g-index

197  
all docs

197  
docs citations

197  
times ranked

68506  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immuno-oncological role of 20S proteasome alpha-subunit 3 in aggravating the progression of esophageal squamous cell carcinoma. <i>European Journal of Immunology</i> , 2022, 52, 338-351.	1.6	1
2	Predicting sulforaphane-induced adverse effects in colon cancer patients via in silico investigation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112598.	2.5	15
3	Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma. <i>Cytotherapy</i> , 2022, , .	0.3	2
4	CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2663-2675.	2.0	11
5	Long Noncoding RNA lncNDEPD1 Regulates PD-1 Expression via miR-3619-5p in CD8+ T Cells. <i>Journal of Immunology</i> , 2022, 208, 1483-1492.	0.4	6
6	m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer. <i>Cell and Bioscience</i> , 2022, 12, 60.	2.1	21
7	High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. <i>Cancer Immunology Research</i> , 2022, 10, 844-855.	1.6	4
8	Intratumor microbiome in cancer progression: current developments, challenges and future trends. <i>Biomarker Research</i> , 2022, 10, .	2.8	25
9	A signature for pan-cancer prognosis based on neutrophil extracellular traps. , 2022, 10, e004210.		52
10	COL5A1 Promotes the Progression of Gastric Cancer by Acting as a ceRNA of miR-137-3p to Upregulate FSTL1 Expression. <i>Cancers</i> , 2022, 14, 3244.	1.7	5
11	Eomes promotes esophageal carcinoma progression by recruiting Treg cells through the CCL20-CCR6 pathway. <i>Cancer Science</i> , 2021, 112, 144-154.	1.7	18
12	L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 547-561.	1.4	9
13	CXCL11 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1302, 41-50.	0.8	17
14	Regulatory T cells promote glioma cell stemness through TGF- $\beta$ -NF- $\kappa$ B-IL6-STAT3 signaling. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2601-2616.	2.0	38
15	Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 661357.	2.2	12
16	Identification of a ceRNA Network in Lung Adenocarcinoma Based on Integration Analysis of Tumor-Associated Macrophage Signature Genes. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 629941.	1.8	9
17	Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 596484.	1.8	7
18	TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 209.	3.5	27

#	ARTICLE	IF	CITATIONS
19	PD-1 Affects the Immunosuppressive Function of Group 2 Innate Lymphoid Cells in Human Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 680055.	2.2	21
20	IL-6/ST2 as a potential target for tumor immunotherapy. <i>European Journal of Immunology</i> , 2021, 51, 1943-1955.	1.6	22
21	Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 96, 107616.	1.7	5
22	Targeting neoantigens for cancer immunotherapy. <i>Biomarker Research</i> , 2021, 9, 61.	2.8	29
23	Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. <i>Translational Oncology</i> , 2021, 14, 101138.	1.7	14
24	Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2021, 518, 35-48.	3.2	76
25	NEDD9 promotes cancer stemness by recruiting myeloid-derived suppressor cells & via CXCL8 in esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 705-720.	1.4	12
26	Myeloid cells in COVID-19 microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 372.	7.1	14
27	Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021, 14, 187.	6.9	82
28	Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway. <i>BMC Medicine</i> , 2021, 19, 283.	2.3	15
29	Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma. <i>Cancer Cell International</i> , 2021, 21, 680.	1.8	6
30	Efficacy of cascade-primed cell infusion as an adjuvant immunotherapy with concurrent chemotherapy for patients with non-small-cell lung cancer: A retrospective observational study with a 5-year follow-up. <i>Cytotherapy</i> , 2020, 22, 35-43.	0.3	3
31	Systematic construction and validation of an immune prognostic model for lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1233-1244.	1.6	52
32	MUC1 as a target for CAR-T therapy in head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 640-652.	1.3	51
33	Roles of IFN- $\gamma$ in tumor progression and regression: a review. <i>Biomarker Research</i> , 2020, 8, 49.	2.8	513
34	Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 803.	1.8	30
35	Point mutation in <i>CD19</i> facilitates immune escape of B cell lymphoma from CAR-T cell therapy. , 2020, 8, e001150.		47
36	PMN- $\alpha$ MDSCs-induced accumulation of CD8+CD39+ T cells predicts the efficacy of chemotherapy in esophageal squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e232.	1.7	5

#	ARTICLE	IF	CITATIONS
37	Metabolic Alterations Related to Glioma Grading Based on Metabolomics and Lipidomics Analyses. <i>Metabolites</i> , 2020, 10, 478.	1.3	18
38	Immunosenescence: a key player in cancer development. <i>Journal of Hematology and Oncology</i> , 2020, 13, 151.	6.9	198
39	COVID-19: immunopathogenesis and Immunotherapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 128.	7.1	535
40	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
41	Mesenchymal Stem Cells Represent a Potential Therapeutic Option for Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome. <i>Engineering</i> , 2020, 6, 1073-1075.	3.2	5
42	Characterization of a non-coding RNA-associated ceRNA network in metastatic lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 11680-11690.	1.6	7
43	Immune characteristics of severe and critical COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 179.	7.1	35
44	An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 182.	7.1	21
45	HMGB1 in inflammation and cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 116.	6.9	117
46	PD-1 abrogates the prolonged persistence of CD8+ CAR-T cells with 4-1BB co-stimulation. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 164.	7.1	9
47	Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1092-1094.	4.8	31
48	A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration. <i>Cancer Science</i> , 2020, 111, 4041-4050.	1.7	47
49	Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	10
50	Gene modification strategies for next-generation CAR T cells against solid cancers. <i>Journal of Hematology and Oncology</i> , 2020, 13, 54.	6.9	98
51	IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2371-2380.	2.0	30
52	Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients. <i>Journal of Hematology and Oncology</i> , 2020, 13, 68.	6.9	45
53	Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 280.	1.8	28
54	Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. <i>Lancet</i> , 2020, 395, 1054-1062.	6.3	21,698

#	ARTICLE	IF	CITATIONS
55	Metformin Enhances the Antitumor Activity of CD8+ T Lymphocytes via the AMPK-miR-107-PD-1 Pathway. <i>Journal of Immunology</i> , 2020, 204, 2575-2588.	0.4	78
56	Interleukin-33-nuclear factor- $\kappa$ B-CCL2 signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells. <i>Cancer Science</i> , 2020, 111, 795-806.	1.7	54
57	Gasdermin-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. <i>Science Immunology</i> , 2020, 5, .	5.6	314
58	Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). <i>Frontiers in Immunology</i> , 2020, 11, 827.	2.2	1,924
59	CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. , 2020, 8, e000131.		64
60	Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 311.	1.3	10
61	Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 54.	7.1	50
62	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , 2020, 12, 681-696.	1.0	14
63	Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580005.	1.8	9
64	DEFB4A is a potential prognostic biomarker for colorectal cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	9
65	MicroRNA-181 inhibits glioblastoma cell growth by directly targeting CCL8. <i>Oncology Letters</i> , 2019, 18, 1922-1930.	0.8	11
66	Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 253.	1.8	32
67	Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF- $\kappa$ B signaling. , 2019, 7, 215.		128
68	CD73: an emerging checkpoint for cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 983-997.	1.0	74
69	Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 903-916.	1.9	5
70	IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF- $\kappa$ B/Notch1 pathway in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019, 145, 1099-1110.	2.3	117
71	Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity. <i>Molecular Cancer</i> , 2019, 18, 108.	7.9	54
72	Establishment of porcine and human expanded potential stem cells. <i>Nature Cell Biology</i> , 2019, 21, 687-699.	4.6	261

#	ARTICLE	IF	CITATIONS
73	TNF- $\alpha$ -induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 165.	1.8	70
74	IL-17A-stimulated endothelial fatty acid $\beta$ -oxidation promotes tumor angiogenesis. <i>Life Sciences</i> , 2019, 229, 46-56.	2.0	18
75	Low-Dose IFN $\beta$ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 3737-3748.	0.4	89
76	GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation. <i>Journal of Oncology</i> , 2019, 2019, 1-15.	0.6	10
77	Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma. <i>OncImmunology</i> , 2019, 8, e1601478.	2.1	53
78	Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis. <i>Cancer Medicine</i> , 2019, 8, 3059-3071.	1.3	9
79	The repertoire features of T cell receptor $\beta$ -chain of different age and gender groups in healthy Chinese individuals. <i>Immunology Letters</i> , 2019, 208, 44-51.	1.1	9
80	Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. <i>Cancer Letters</i> , 2019, 452, 244-253.	3.2	120
81	Targeting NR4As, a new strategy to fine-tune CAR-T cells against solid tumors. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 7.	7.1	5
82	Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2019, 112, 108632.	2.5	19
83	Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. , 2019, 7, 42.		122
84	Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2019, 12, 125.	6.9	116
85	Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. <i>Journal of Hematology and Oncology</i> , 2019, 12, 127.	6.9	44
86	A cycle involving HMGB1, IFN $\beta$ and dendritic cells plays a putative role in anti-tumor immunity. <i>Cellular Immunology</i> , 2019, 343, 103850.	1.4	17
87	Fates of CD8+ T cells in Tumor Microenvironment. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 1-13.	1.9	321
88	The R132H mutation in <i>IDH1</i> promotes the recruitment of <i>NK</i> cells through <i>CXCL1</i> / <i>CXCR3</i> chemotaxis and is correlated with a better prognosis in gliomas. <i>Immunology and Cell Biology</i> , 2019, 97, 457-469.	1.0	48
89	CDR3 repertoire diversity of CD8+ T lymphocytes in patients with HCV. <i>Cellular Immunology</i> , 2019, 336, 34-39.	1.4	1
90	Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with <i>IDH1</i> Mutation. <i>Journal of Proteome Research</i> , 2019, 18, 960-969.	1.8	56

#	ARTICLE	IF	CITATIONS
91	CD73 expression on effector T cells sustained by TGF- $\beta$ 2 facilitates tumor resistance to anti-4-1BB/CD137 therapy. <i>Nature Communications</i> , 2019, 10, 150.	5.8	66
92	Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signalling. <i>Journal of Viral Hepatitis</i> , 2019, 26, 246-257.	1.0	10
93	Efficacy of Early Enteral Immunonutrition on Immune Function and Clinical Outcome for Postoperative Patients With Gastrointestinal Cancer. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 758-765.	1.3	18
94	Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. <i>Oncolmmunology</i> , 2018, 7, e1442167.	2.1	67
95	Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. <i>Cancer Research</i> , 2018, 78, 1779-1791.	0.4	202
96	MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 83.	3.5	65
97	T-cell receptor-engineered T cells for cancer treatment: current status and future directions. <i>Protein and Cell</i> , 2018, 9, 254-266.	4.8	124
98	A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells. <i>Nature Cell Biology</i> , 2018, 20, 21-27.	4.6	130
99	Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy. <i>Journal of Immunotherapy</i> , 2018, 41, 406-410.	1.2	35
100	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 157-172.	0.7	40
101	IL-33 in Tumor Immunity: Nothing to Sneeze At. <i>Critical Reviews in Immunology</i> , 2018, 38, 453-470.	1.0	7
102	Specific clinical and immune features of CD68 in glioma via 1,024 samples. <i>Cancer Management and Research</i> , 2018, Volume 10, 6409-6419.	0.9	21
103	Episcleritis in a patient with mucosal melanoma treated with interferon alfa-2b and radiotherapy: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 388.	0.4	2
104	Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. <i>Oncolmmunology</i> , 2018, 7, e1461304.	2.1	59
105	Regulatory T cells were recruited by CCL3 to promote cryo-injured muscle repair. <i>Immunology Letters</i> , 2018, 204, 29-37.	1.1	16
106	Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression. <i>Journal of Immunology</i> , 2018, 201, 3456-3464.	0.4	59
107	Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF- $\kappa$ B/Notch1 signaling in non-small cell lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1461303.	2.1	25
108	Role of CXCR7 as a Common Predictor for Prognosis in Solid Tumors: a Meta-Analysis. <i>Journal of Cancer</i> , 2018, 9, 3138-3148.	1.2	8

#	ARTICLE	IF	CITATIONS
109	Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	102
110	Dual TGF $\beta$ 2 and PD $\beta$ 1 blockade synergistically enhances MAGEA3-specific CD8 <sup>+</sup> T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2561-2574.	2.3	68
111	Regulation of Memory CD8 <sup>+</sup> T Cell Differentiation by MicroRNAs. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 2187-2198.	1.1	18
112	Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes. <i>Clinical Lung Cancer</i> , 2018, 19, e675-e683.	1.1	12
113	Interleukin 8 (CXCL8)-CXC chemokine receptor 2 (CXCR2) axis contributes to MiR-4437-associated recruitment of granulocytes and natural killer cells in ischemic stroke. <i>Molecular Immunology</i> , 2018, 101, 440-449.	1.0	17
114	miR-143 Regulates Memory T Cell Differentiation by Reprogramming T Cell Metabolism. <i>Journal of Immunology</i> , 2018, 201, 2165-2175.	0.4	51
115	Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1/RelA/IL8 Signaling Pathway. <i>Cancer Immunology Research</i> , 2018, 6, 1246-1259.	1.6	28
116	Identification of liver metastasis-associated genes in human colon carcinoma by mRNA profiling. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 633-646.	0.7	15
117	Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer. <i>Current Stem Cell Research and Therapy</i> , 2018, 13, 327-335.	0.6	6
118	Tumor-associated macrophages: from basic research to clinical application. <i>Journal of Hematology and Oncology</i> , 2017, 10, 58.	6.9	607
119	Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 1609-1618.	0.8	36
120	The development of hepatocarcinoma after long-term antiviral treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 311-318.	0.7	17
121	CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF $\beta$ 2-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1320011.	2.1	205
122	Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer. <i>International Immunopharmacology</i> , 2017, 46, 170-177.	1.7	12
123	Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. <i>Journal of Immunology</i> , 2017, 198, 1365-1375.	0.4	80
124	WASH overexpression enhances cancer stem cell properties and correlates with poor prognosis of esophageal carcinoma. <i>Cancer Science</i> , 2017, 108, 2358-2365.	1.7	19
125	WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. <i>Oncology Letters</i> , 2017, 14, 3580-3586.	0.8	29
126	<i>Pseudomonas aeruginosa</i> -mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies. <i>International Immunopharmacology</i> , 2017, 51, 57-65.	1.7	19



#	ARTICLE	IF	CITATIONS
127	Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 299-308.	2.0	11
128	Target of obstructive sleep apnea syndrome merge lung cancer: based on big data platform. <i>Oncotarget</i> , 2017, 8, 21567-21578.	0.8	44
129	Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer. <i>Oncology Reports</i> , 2017, 37, 2771-2778.	1.2	9
130	Cancer Immunology and Cancer Immunodiagnosis 2016. <i>Journal of Immunology Research</i> , 2017, 2017, 1-1.	0.9	3
131	Tumor-associated macrophages, potential targets for cancer treatment. <i>Biomarker Research</i> , 2017, 5, 25.	2.8	53
132	Identification of 14â€“3-3Î¶ as a potential biomarker in gastric cancer by proteomics-based analysis. <i>Molecular Medicine Reports</i> , 2017, 16, 7759-7765.	1.1	8
133	Musashi1, a potential prognostic marker in esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2017, 38, 1724-1732.	1.2	12
134	Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma. <i>Histology and Histopathology</i> , 2017, 32, 793-803.	0.5	8
135	miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 86592-86603.	0.8	60
136	Gene function analysis and underlying mechanism of esophagus cancer based on microarray gene expression profiling. <i>Oncotarget</i> , 2017, 8, 105222-105237.	0.8	16
137	Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10.	1.9	197
138	MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD. <i>BMC Cancer</i> , 2016, 16, 315.	1.1	44
139	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	0.8	76
140	Long noncoding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting Î²-catenin <i>via</i> Ezh2. <i>Oncotarget</i> , 2016, 7, 25668-25682.	0.8	90
141	Hepatitis C virus core protein impairs metabolic disorder of liver cell via HOTAIR-Sirt1 signalling. <i>Bioscience Reports</i> , 2016, 36, .	1.1	23
142	Autoantibodies against tumor-associated antigens in the early detection of lung cancer. <i>Lung Cancer</i> , 2016, 99, 172-179.	0.9	62
143	Impaired T cell function in malignant pleural effusion is caused by TGFâ€“ $\beta$ 2 derived predominantly from macrophages. <i>International Journal of Cancer</i> , 2016, 139, 2261-2269.	2.3	62
144	Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/Î²-catenin pathway in esophageal squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 98.	3.5	75

#	ARTICLE	IF	CITATIONS
145	Long-Peptide Cross-Presentation by Human Dendritic Cells Occurs in Vacuoles by Peptide Exchange on Nascent MHC Class I Molecules. <i>Journal of Immunology</i> , 2016, 196, 1711-1720.	0.4	40
146	Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression. <i>OncolImmunology</i> , 2016, 5, e1118599.	2.1	85
147	TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 293-304.	2.0	41
148	Dynamic changes in CD45RA <sup>+</sup> Foxp3 <sup>high</sup> regulatory T-cells in chronic hepatitis C patients during antiviral therapy. <i>International Journal of Infectious Diseases</i> , 2016, 45, 5-12.	1.5	7
149	Targeting Ornithine Decarboxylase by $\hat{\pm}$ -Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2016, 196, 915-923.	0.4	55
150	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , 2016, 17, 95-103.	7.0	310
151	Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 61069-61080.	0.8	44
152	Immunotherapy for lung cancer: advances and prospects. <i>American Journal of Clinical and Experimental Immunology</i> , 2016, 5, 1-20.	0.2	28
153	Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. <i>Oncology Reports</i> , 2015, 33, 425-432.	1.2	44
154	Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. <i>Oncotarget</i> , 2015, 6, 33961-33971.	0.8	113
155	CD163 <sup>+</sup> tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. <i>Oncotarget</i> , 2015, 6, 10592-10603.	0.8	78
156	CD163 <sup>+</sup> CD14 <sup>+</sup> macrophages, a potential immune biomarker for malignant pleural effusion. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 965-976.	2.0	41
157	Efficacy and safety of cord blood <sup>+</sup> derived cytokine-induced killer cells in treatment of patients with malignancies. <i>Cytotherapy</i> , 2015, 17, 1130-1138.	0.3	20
158	Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer. <i>Experimental Cell Research</i> , 2015, 336, 141-149.	1.2	38
159	Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. <i>Cancer Letters</i> , 2015, 362, 192-198.	3.2	44
160	The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. <i>Archives of Virology</i> , 2015, 160, 1043-1054.	0.9	3
161	Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell <sup>+</sup> Dependent Mechanism. <i>Cancer Research</i> , 2015, 75, 519-531.	0.4	92
162	Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. <i>Cytotherapy</i> , 2015, 17, 86-97.	0.3	18

#	ARTICLE	IF	CITATIONS
163	Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs. <i>Cancer Cell &amp; Microenvironment</i> , 2015, 2, .	0.8	31
164	Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 24978-24989.	0.8	91
165	MicroRNA-155 regulates tumor myeloid-derived suppressive cells. <i>Oncoscience</i> , 2015, 2, 910-911.	0.9	1
166	The NF $\kappa$ B inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. <i>Cancer Biology and Therapy</i> , 2014, 15, 602-611.	1.5	18
167	Cancer Immunology and Cancer Immunodiagnosis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-2.	0.9	11
168	Evaluation of Combined Argon Plasma Coagulation and Savary Bougienage for the Relief of Anastomotic-Stenosis after Esophageal Squamous Cancer Surgery. <i>Digestive Surgery</i> , 2014, 31, 415-421.	0.6	3
169	<i>Pseudomonas aeruginosa</i> injection enhanced antitumor cytotoxicity of cytokine-induced killer cells derived from cord blood. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 1057-1063.	2.5	6
170	Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	0.9	12
171	Evaluation of Diagnostic Value in Using a Panel of Multiple Tumor-Associated Antigens for Immunodiagnosis of Cancer. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	0.9	14
172	Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	107
173	Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 551-556.	2.5	5
174	Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma. <i>Experimental Cell Research</i> , 2014, 322, 149-158.	1.2	27
175	Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. <i>Oncology Reports</i> , 2014, 32, 2244-2252.	1.2	14
176	Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamous cell carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 751-755.	2.5	24
177	Functional recovery after transplantation of induced pluripotent stem cells in a rat hemorrhagic stroke model. <i>Neuroscience Letters</i> , 2013, 554, 70-75.	1.0	26
178	Transplantation of human neuro-epithelial-like stem cells derived from induced pluripotent stem cells improves neurological function in rats with experimental intracerebral hemorrhage. <i>Neuroscience Letters</i> , 2013, 548, 95-100.	1.0	32
179	The expression of immediate early response gene X-1 in preeclampsia placenta and its pro-apoptotic role in preeclampsia. <i>Hypertension in Pregnancy</i> , 2013, 32, 157-168.	0.5	3
180	Graft-versus-Host Disease Is Enhanced by Selective CD73 Blockade in Mice. <i>PLoS ONE</i> , 2013, 8, e58397.	1.1	37

#	ARTICLE	IF	CITATIONS
181	Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer. <i>Cancer Letters</i> , 2012, 322, 70-77.	3.2	78
182	Alteration of renal cyclooxygenase expression due to partial unilateral ureteral obstruction in neonatal. <i>Canadian Urological Association Journal</i> , 2012, 6, E150-5.	0.3	1
183	CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2371-2382.	3.9	221
184	CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 851-862.	2.0	36
185	Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity. <i>PLoS Pathogens</i> , 2010, 6, e1001018.	2.1	46
186	Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein. <i>Journal of Immunology</i> , 2005, 174, 2404-2411.	0.4	37
187	Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules. <i>Journal of Immunology</i> , 2004, 172, 6649-6657.	0.4	182
188	A MAGE-3 Peptide Presented by HLA-DR1 to CD4+T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein. <i>Journal of Immunology</i> , 2003, 171, 219-225.	0.4	43
189	Tumor-specific shared antigenic peptides recognized by human T cells. <i>Immunological Reviews</i> , 2002, 188, 51-64.	2.8	356
190	Immunotherapy for Esophageal Cancer. , 0, , .		1